CSIMarket Company Name, Ticker, Customers, else..
 
Regulus Therapeutics Inc   (NASDAQ: RGLS)
Other Ticker:  
 
 
Price: $1.3700 $0.01 0.735%
Day's High: $1.4 Week Perf: 0.00
Day's Low: $ 1.35 30 Day Perf: 7.87 %
Volume (M): 265 52 Wk High: $ 3.00
Volume (M$): $ 362 52 Wk Avg: $1.73
Open: $1.37 52 Wk Low: $0.83



 Market Capitalization (Millions $) 77
 Shares Outstanding (Millions) 57
 Employees 50
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) 15
 Capital Exp. (TTM) (Millions $) 0

Regulus Therapeutics Inc
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of various diseases, primarily in the field of RNA therapeutics. The company has its headquarters in San Diego, California, and was founded in 2007 by two leading biotechnology companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.

Regulus Therapeutics is dedicated to discovering and developing first-in-class and best-in-class medicines for the treatment of diseases like renal, hepatic, and metabolic disorders, as well as immune-oncology and neurodegenerative conditions. Regulus is involved in the development of a broad portfolio of therapeutic products for diseases such as chronic hepatitis C, liver fibrosis, and autoimmune diseases.

The company's approach is focused on research and development of microRNA (miR) therapeutics, which allows the company to harness the potent regulation of miRNA biology to treat various diseases through selective modulation of the targets of specific miRNAs. This unique approach has positioned Regulus Therapeutics as a leading player in the emerging field of RNA-based therapeutics.

Regulus Therapeutics' pipeline of development encompasses five product candidates in different stages of development for different indications. RGLS4326 is their leading product candidate; it treats Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic disease characterized by the build-up of cysts in the kidneys, which eventually leads to renal failure. Their second leading product candidate is RGLS5579, used to treat Cholangiocarcinoma, also known as bile duct cancer.

Regulus Therapeutics has collaborations with leading academic and pharmaceutical companies in the RNA therapeutics field, including Roche and Sanofi, which help the company gain access to new technologies and provide vital support in carrying out their pre-clinical and clinical studies.

In summary, Regulus Therapeutics is a cutting-edge biopharmaceutical company dedicated to the development of RNA therapeutics to and innovations that address unmet medical needs through the selective modulation of miRNA targets, with a strong focus on addressing kidney diseases and immuno-oncology.


   Company Address: 4224 Campus Point Court, Suite 210 San Diego 92121 CA
   Company Phone Number: 202-6300   Stock Exchange / Ticker: NASDAQ RGLS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY        11.94% 
IONS   -4.05%    
PTCT   -0.05%    
REGN   -2.94%    
SRPT   -26.89%    
UTHR   -3.08%    
• View Complete Report
   



Regulus Therapeutics Inc

Regulus Therapeutics Inc Unveils $8.125 Million Operating Loss, Marking a Pivotal Moment in Q3 2023 Earnings

Regulus Therapeutics Inc Faces Challenging Quarter, Raises Questions About Future Performance
In the Major Pharmaceutical Preparations sector, while large companies have been in the spotlight, a few overlooked entities are starting to make waves with their financial numbers. One such company is Regulus Therapeutics Inc (RGLS), which recently reported an operating loss of $-8.125 million for the third quarter of 2023.
Although the emerging growth business did not disclose its revenue for the same period, it is essential to gauge its current efforts in the context of its corporate performance from the previous year. In the third quarter of 2022, Regulus Therapeutics Inc recorded an operating loss of $-7.563 million, suggesting that the company's losses have slightly intensified.
Regulus Therapeutics Inc

Regulus Therapeutics Inc Reveals Worsening Operating Loss in Q2 2023 Amidst Challenging Market Conditions



As the reporting season for April to June 2023 gains momentum, various businesses within the Major Pharmaceutical Preparations sector have released their financial numbers. Regulus Therapeutics Inc (RGLS), an emerging growth corporation, recently declared an operating loss of $-7.315 million for the mentioned period. Although the respective revenue figures are yet to be disclosed, it is essential to compare these results with the previous year to provide context. In Q2 of 2022, Regulus Therapeutics Inc reported an operating loss of $-6.569 million. Investors are now eagerly anticipating the future performance of the company amidst challenging market conditions.
Revenue Challenges and Declining Accounts Receivable:
Regulus Therapeutics Inc's second-quarter earnings season of 2023 experienced some adverse trends, resulting in a widened operating loss of $-7.013 million. Analysts suggest that the decline in accounts receivable to $0.0 million may be indicative of slowing demand within the pharmaceutical sector. This fuzzy patch serves as a reminder that even businesses with lucrative revenue streams occasionally face obstacles.
Regulus Therapeutics Inc

Regulus Therapeutics Inc Shows Promise with Operating Shortfall Improvement despite Q1 Net Loss

Regulus Therapeutics Inc, a biotechnology company that develops RNA-based therapeutics, faced a challenging time in the first quarter of 2023 with a net loss of $-27 million. This has resulted in a negative return on equity (ROE) of -70.85%. The company's total ranking has deteriorated compared to the fourth quarter of 2022, falling from 0 to 2464. Within the Major Pharmaceutical Preparations industry, 159 other companies had a higher return on equity, indicating the company's underperformance in the industry.
The pharmaceutical industry contributors are analyzing the results of the first quarter of 2023 and are currently following an operating shortfall of $-7.369 million from Regulus Therapeutics Inc, as the company has not cited any revenue as yet. Despite this, it is worth noting that the company has been becoming more efficient in conducting its business. In the comparable period last year, Regulus Therapeutics Inc reported an operating shortfall of $-8.419 million, which has improved to $-7.139 million in the fiscal period ending in March 31, 2023. This improvement has occurred even as the company is still developing its business model.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com